Executive vice president and president of Lilly Oncology
Appears in 1 story
Leads Jaypirca commercial strategy at Eli Lilly
The FDA on October 2 approved Eli Lilly's Jaypirca for newly diagnosed chronic lymphocytic leukemia, making it the first non-covalent BTK inhibitor available as initial therapy. The approval covers adults with previously untreated CLL or small lymphocytic lymphoma who lack a 17p deletion, a subgroup that makes up roughly 92% to 95% of new cases.
Updated 2 hours ago
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
